Retatrutide has generated enormous interest for one headline-grabbing reason: in a Phase 2 obesity trial, participants receiving the highest studied dose lost an average of roughly 24% of their body weight over 48 weeks. That approaches results historically associated with bariatric surgery, but it came from a controlled trial, not